Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Experiences of antipsychotic use in patients with early psychosis: a two-year follow-up study.

Yeisen RAH, Bjornestad J, Joa I, Johannessen JO, Opjordsmoen S.

BMC Psychiatry. 2017 Aug 22;17(1):299. doi: 10.1186/s12888-017-1425-9.

2.

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.

Decuypere F, Sermon J, Geerts P, Denee TR, De Vos C, Malfait B, Lamotte M, Mulder CL.

PLoS One. 2017 Jun 14;12(6):e0179049. doi: 10.1371/journal.pone.0179049. eCollection 2017.

3.

Motivation deficits and use of alcohol and illicit drugs among individuals with schizophrenia.

Bahorik AL, Greeno CG, Cochran G, Cornelius JR, Eack SM.

Psychiatry Res. 2017 Jul;253:391-397. doi: 10.1016/j.psychres.2017.04.012. Epub 2017 Apr 5.

PMID:
28441618
4.

Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.

Blanco-Silvente L, Castells X, Saez M, Barceló MA, Garre-Olmo J, Vilalta-Franch J, Capellà D.

Int J Neuropsychopharmacol. 2017 Feb 13. doi: 10.1093/ijnp/pyx012. [Epub ahead of print]

5.

Realising stratified psychiatry using multidimensional signatures and trajectories.

Joyce DW, Kehagia AA, Tracy DK, Proctor J, Shergill SS.

J Transl Med. 2017 Jan 18;15(1):15. doi: 10.1186/s12967-016-1116-1.

6.

Multi-Objective Markov Decision Processes for Data-Driven Decision Support.

Lizotte DJ, Laber EB.

J Mach Learn Res. 2016;17. pii: 211. Epub 2016 Dec 1.

7.

One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study.

Ye W, Fujikoshi S, Nakahara N, Takahashi M, Ascher-Svanum H, Ohmori T.

Pragmat Obs Res. 2012 Jun 13;3:41-49. eCollection 2012.

8.

Sequential multiple assignment randomization trials with enrichment design.

Liu Y, Wang Y, Zeng D.

Biometrics. 2017 Jun;73(2):378-390. doi: 10.1111/biom.12576. Epub 2016 Sep 6.

9.

Visualization of Categorical Longitudinal and Times Series Data.

Tueller SJ, Van Dorn RA, Bobashev GV.

Methods Rep RTI Press. 2016 Feb;2016. pii: MR-0033-1602.

10.

The latent structure of psychiatric symptoms across mental disorders as measured with the PANSS and BPRS-18.

Van Dorn RA, Desmarais SL, Grimm KJ, Tueller SJ, Johnson KL, Sellers BG, Swartz MS.

Psychiatry Res. 2016 Nov 30;245:83-90. doi: 10.1016/j.psychres.2016.08.029. Epub 2016 Aug 9.

11.

Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record.

Lui K, Randhawa G, Totten V, Smith AE, Raese J.

Prim Care Companion CNS Disord. 2016 Jan 28;18(1). doi: 10.4088/PCC.15m01849. eCollection 2016.

12.

A case study of SMART attributes: a qualitative assessment of generalizability, retention rate, and trial quality.

Moodie EE, Karran JC, Shortreed SM.

Trials. 2016 May 14;17(1):242. doi: 10.1186/s13063-016-1368-3. Review.

13.

Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.

Tsuneyama N, Suzuki Y, Sawamura K, Sugai T, Fukui N, Watanabe J, Ono S, Saito M, Someya T.

PLoS One. 2016 Mar 1;11(3):e0149518. doi: 10.1371/journal.pone.0149518. eCollection 2016.

14.

Q-learning residual analysis: application to the effectiveness of sequences of antipsychotic medications for patients with schizophrenia.

Ertefaie A, Shortreed S, Chakraborty B.

Stat Med. 2016 Jun 15;35(13):2221-34. doi: 10.1002/sim.6859. Epub 2016 Jan 10.

15.

A Role for Oxytocin in the Etiology and Treatment of Schizophrenia.

Rich ME, Caldwell HK.

Front Endocrinol (Lausanne). 2015 Jun 3;6:90. doi: 10.3389/fendo.2015.00090. eCollection 2015. Review.

16.

Endophenotypes in Schizophrenia for the Perinatal Period: Criteria for Validation.

Ross RG, Freedman R.

Schizophr Bull. 2015 Jul;41(4):824-34. doi: 10.1093/schbul/sbv054. Epub 2015 May 4. Review.

17.

Prediction of treatment outcomes in psychiatry--where do we stand ?

McMahon FJ.

Dialogues Clin Neurosci. 2014 Dec;16(4):455-64. Review.

18.

Antipsychotics and amotivation.

Fervaha G, Takeuchi H, Lee J, Foussias G, Fletcher PJ, Agid O, Remington G.

Neuropsychopharmacology. 2015 May;40(6):1539-48. doi: 10.1038/npp.2015.3. Epub 2015 Jan 8.

19.

Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.

Nakajima S, Takeuchi H, Fervaha G, Plitman E, Chung JK, Caravaggio F, Iwata Y, Mihashi Y, Gerretsen P, Remington G, Mulsant B, Graff-Guerrero A.

Schizophr Res. 2015 Feb;161(2-3):429-33. doi: 10.1016/j.schres.2014.12.024. Epub 2014 Dec 30.

20.

The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.

Løberg EM, Helle S, Nygård M, Berle JØ, Kroken RA, Johnsen E.

Front Psychiatry. 2014 Nov 18;5:159. doi: 10.3389/fpsyt.2014.00159. eCollection 2014.

Supplemental Content

Support Center